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Abstract 
Moderate to severe traumatic brain injury (TBI), where there is gross damage to the brain 
parenchyma, may be diagnosed by clinical assessment and standard neuroimaging techniques. 
In contrast, diagnostic tools for mild TBI or concussion are lacking; currently, the diagnosis 
has to be made on clinical grounds. Most mild TBI patients recover quickly but a proportion 
develop an ill-defined condition called post-concussive syndrome (PCS). Repetitive 
concussions have also been associated with a chronic neurodegenerative disorder called 
chronic traumatic encephalopathy (CTE), which is a diagnosis that only can be made post 
mortem. There is an unmet clinical need of diagnostic and prognostic biomarkers for mild 
TBI. We also need research tools to better define PCS and to detect CTE in vivo. Here, we 
review the literature on fluid biomarkers for neuronal, axonal, oligodendrocytic, astroglial and 
blood-brain barrier injury, as well as neuroinflammation and metabolic dysregulation, in the 
context of mild TBI and related conditions. We also discuss technical and standardisation 
issues and potential pathways forwards regarding how to move the most promising biomarker 
candidates into clinical laboratory practice.  
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Key points:  
 Traumatic brain injury is caused by an external mechanical force injuring the brain 
parenchyma. 
 Repetitive mild traumatic brain injury may cause long-term symptoms and progressive 
neurodegeneration, but how big this risk is, is unknown. 
 Mild traumatic brain injury is hard to diagnose objectively; accurate fluid biomarkers 
would be a welcome addition to the diagnostic toolbox. 
 Fluid biomarkers for axonal injury and astroglial activation show the greatest promise 
at the moment but several other promising biomarker candidates exist. 
 Brain specificity or brain-enhanced expression is an important characteristic of blood-
based biomarkers for mild traumatic brain injury, as extra-cerebral sources otherwise 
may compromise the interpretability of the test results.  
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Review criteria: 
We searched PubMed for articles in the English language on mild traumatic brain injury 
(TBI) and related conditions using the keywords “TBI” or “traumatic brain injury” or 
“concussion”, in combination with “biomarkers”, “CSF”, “plasma”, “serum”, “blood”, “mild 
traumatic brain injury”, “mild TBI”, “post-concussive/concussion syndrome”, “PCS”, 
“chronic traumatic encephalopathy” or “CTE”. We selected articles examining fluid 
biomarker changes in mild TBI, PCS and CTE. We also included articles examining 
biomarkers in moderate to severe TBI, when of relevance to mild TBI, PCS and/or CTE. 
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Introduction 
Traumatic brain injury (TBI) is caused by an external mechanical force impacting the brain.  
Moderate to severe TBI, in which there are intracranial bleedings and/or mass lesions in the 
brain parenchyma, is diagnosed by clinical examination and standard neuroimaging 
techniques, such as computed tomography (CT) or magnetic resonance imaging (MRI) of the 
brain.1 Clinically, TBI may also be graded using the Glasgow Coma Scale, in which the 
patient’s conscious state is rated on the basis of eye, verbal and motor responses to different 
stimuli.2 However, the prognostic utility of this and similar scales is under debate and 
additional sub-classification with novel biomarkers remains an unmet clinical need, as 
extensively discussed elsewhere.3  
 
Mild TBI or concussion (the terms are synonymous) is defined as a head trauma resulting in 
brief loss of consciousness and/or alteration of mental state (Box 1), which is hard to 
objectively diagnose. Today, this is a clinical diagnosis based on self-reported symptoms after 
blunt head injury and presents an everyday challenge in emergency care units around the 
world. There are several reasons for why the diagnosis should not be neglected. First, 
approximately 7-20% of consecutive patients presenting to the emergency room with 
suspected concussion have an intra-cranial abnormality (e.g., contusion or haemorrhage) on a 
day-of-injury CT scan.4 Second, a significant number of mild TBI patients get incapacitating 
symptoms for >10 days following the injury, which is often termed post-concussive syndrome 
(PCS).5 Third, reports linking chronic traumatic encephalopathy (CTE) with repetitive mild 
TBI suggest that care should be taken to minimise the risk of a new concussion before proper 
recovery has been secured.5  
 
 8
Concussion/mild TBI per se causes no gross pathology, such as haemorrhage, and no 
abnormalities on conventional CT scans of the brain,6 but rather rapid-onset neuronal 
dysfunction that often resolves in a spontaneous manner over a few days to weeks. The major 
cause of the symptoms in mild TBI is thought to be axonal injury caused by rapid stretching 
of the axons due to acceleration/deceleration and/or rotational forces on the brain 
parenchyma.5 Neuroinflammation/microglial activation may also play a role. Novel MRI 
techniques, e.g., diffusion tensor imaging (DTI), may be used to monitor axonal integrity, but 
conclusive evidence on their sensitivity to detect axonal injury in mild TBI is lacking.7,8 
 
Approximately 15% of concussion patients suffer cognitive or neurological dysfunction that 
continues for months or more after the initial injury.9,10 Such patients may fulfil criteria for 
PCS.11 PCS has been the subject of intense debate, since the diagnosis is associated with quite 
a wide range of symptoms (physical, such as headache; cognitive, such as difficulty 
concentrating; and emotional/behavioural, such as irritability), and since the risk of PCS is 
influenced not only by injury mechanisms but also by psychological and socioeconomic 
factors.12 It is not known what causes PCS to occur and persist.12-14  
 
Repetitive concussions are thought to be a risk factor for CTE, a neuropathological diagnosis 
that was first described in boxers,15 but more recently also in other sports athletes, as well as 
in military veterans.16 Clinically, the condition is characterized by chronic and sometimes 
progressive neurological and/or psychiatric symptoms.16 The molecular pathology of CTE is 
characterized by tau-positive neurofibrillary tangles and neuropil threads that may be present 
in all regions of the brain.16 Neurofibrillary tangles in CTE form preferentially in the 
superficial cortical layers, rather than in deeper layers as is more common in Alzheimer’s 
disease, with focal accumulations at the depths of the sulci.17 Another distinctive (perhaps the 
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most distinctive) feature of CTE is perivascular tau deposition, which may reflect an 
association of tau deposition with TBI-related injury to cerebrovascular endothelial cells, 
which by unknown mechanisms may promote tau deposition.17 The relation between PCS and 
future development of CTE is unknown. Potentially, a fraction of PCS patients will eventually 
be diagnosed with CTE; the size of this fraction is currently unknown given the lack of in vivo 
tools to diagnose CTE in living humans.  
 
Biomarkers 
A fluid biomarker is defined as a molecule that is measureable (as a concentration or an 
activity, or as a qualitatively distinct form of the molecule) in a biological fluid for which the 
measure relates to a physiological or pathological process occurring in a living cell or 
organism. In TBI research and clinical work-up, fluid biomarkers have the potential to help to 
define: (i) TBI severity (including the severity of different types of injury, e.g., axonal injury 
and microvascular damage); (ii) adaptive and recovery processes following TBI; (iii) the 
transition between a normal injury/recovery pattern and a progressive CTE process; and (iv) 
treatment response in clinical trials. For most of the biomarker candidates discussed below 
these potential contexts of use have not yet been defined in appropriate clinical settings.  
 
Sample types for fluid biomarker research in TBI 
Cerebrospinal fluid 
Cerebrospinal fluid (CSF) is a clear fluid that surrounds the brain and provides mechanical 
support. It also carries nutrients and signalling molecules to neurons and helps disposing 
metabolites that are further cleared into the blood via arachnoid villi in the intracranial dural 
sinuses and at the cranial and spinal nerve root sheaths,18 as well as through meningeal 
lymphatic vessels.19 The recent discovery of the so-called glymphatic system has helped 
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explaining how subarachnoid CSF may enter and exit the brain along paravascular spaces and 
clear the brain parenchyma from extracellular metabolites and other breakdown products.20 
The total CSF volume is around 150 mL and the production and clearance rate is around 20 
mL per hour. Standard operating procedures for CSF sampling via lumbar puncture have been 
established and the procedure can be performed in outpatients.21 Lumbar puncture is safe with 
post-lumbar puncture headache being the only significant side-effect that affects 2-20% of the 
patients.22 In severe TBI, CSF may be sampled through intra- or extraventricular catheters but 
it is important to take into account that intracranial CSF differs in protein composition from 
lumbar CSF, so that biomarker concentrations from the two fluid types cannot be compared 
directly.23 The main advantage of CSF as a matrix in which to measure markers of CNS injury 
is that it communicates freely with the brain interstitial fluid that bathes the neurons. 
Biochemical changes in the brain are thus often reflected in the CSF, which may be regarded 
as an accessible, although not perfect, sample of the brain interstitial fluid. Further, CSF has 
low protease activity and most molecules do not change upon sampling provided the sample 
is not contaminated by blood. The main disadvantage is that lumbar puncture may be regarded 
as invasive. Finally, although CSF allows sampling from the brain side of the blood-brain 
barrier, it should be remembered that only 20-30% of the CSF volume is derived from the 
brain; 70-80% is a filtrate of plasma, produced by the choroid plexus.18  
 
Blood 
The other major biofluid for TBI biomarker analysis is blood (serum or plasma), which 
communicates with the brain and CSF compartments through the glymphatic system.20 There 
are several issues, both biological and technical, with the measurement of CNS-related 
biomarkers in blood. First, a biomarker that has its origin in the CNS has to cross the blood-
brain barrier in order to be detected in the periphery and, if the concentration is low in CSF, it 
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will be even lower in the blood due to the blood:CSF volume ratio causing a substantial 
dilution. Second, if the biomarker is not specific for the CNS but also expressed in peripheral 
tissues that may be injured in trauma, the contribution from CNS will potentially drown in the 
high biological background caused by non-CNS sources (a good tool to assess the risk for this 
is the publicly available web-based Human Protein Atlas, http://www.proteinatlas.org/, which 
presents mRNA and protein expression in 44 different human tissues of close to 20000 
proteins).24 Third, the huge amount of other proteins in blood (e.g., albumin and 
immunoglobulins) introduces analytical challenges due to possible interference.25 Fourth, 
heterophilic antibodies may be present in blood, which may interfere in immunoassays (see 
below for more details).26 Fifth, the analyte of interest may undergo proteolytic degradation 
by various proteases in plasma.27 Sixth, clearance of the biomarker in the liver or by the 
kidneys may introduce variability. Finally, recent data, derived from a mouse model of TBI, 
suggest that sleep deprivation and cisternotomy may inhibit glymphatic clearance and thereby 
suppress TBI-induced increases in serum biomarkers.28 Whether this potential confounder is 
relevant also in humans remains to be examined.  
 
Saliva, urine and tears 
It is possible that some CNS-derived proteins are eventually excreted into body fluids other 
than CSF and blood. The presence of the CNS-enriched protein tau in saliva has been 
demonstrated using mass spectrometry.29 The same research group has also detected 
Parkinson-related α-synuclein and DJ-1 in this body fluid.30 However, the relationship 
between salivary concentrations of these proteins to processes within the CNS is far from 
clear and no conclusive data on disease association has been reported so far. At present, it is 
hard to imagine how a test based on sampling of saliva, urine or tears could produce results 
with a clear link to changes in the brain, given the many barriers and compartments the 
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marker has to cross on its way to the sampling site. Further, expression of, e.g., tau mRNA 
and protein in both salivary glands and kidney 
(http://www.proteinatlas.org/ENSG00000186868-MAPT/tissue), may limit the 
interpretability of measurements in these fluids further. Since these fluids, in our opinion, are 
unlikely to yield useful markers, they will not be discussed further.  
 
Measurement techniques 
Most biomarker assays of relevance to TBI are immunochemical, i.e., utilise antibodies to 
quantify a substance in a sample. The most common assay format is the sandwich enzyme-
linked immunosorbent assay (ELISA) in which the target analyte is captured between two 
antibodies in a complex and one of the antibodies carries a signal generator, i.e., an enzyme 
that converts a substrate into a detectable form (coloured, fluorescent or luminescent), which, 
in combination with a calibrator curve (derived from artificial samples with known analyte 
concentrations), allows for quantification of the analyte of interest. ELISA is a theme with 
many variations, such as the choice of signal generator where the enzyme can be replaced by, 
e.g., a fluorophore or a DNA-based detection system.  
 
Immunochemical assays may also be multiplexed in different ELISA-like formats to allow for 
the simultaneous measurement of markers reflecting distinct and unique axes of the 
pathobiology of TBI in the same sample. Such biomarker panels are frequently examined in 
the current biomarker literature with focus on CNS disorders,31 and could potentially provide 
more comprehensive and complementary information and permit a more accurate 
characterization and risk stratification of patients with TBI. A downside with multiplexing, 
however, is that it may be hard to optimize the analytical conditions for several antigen-
antibody interactions, especially if their concentrations or biochemical characteristics 
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substantially differ, as compared to optimizing an assay that focuses on the accurate 
measurement of a single analyte. 
 
The technical issues are mainly a question of antibody sensitivity and specificity. In theory, if 
the time for the enzyme reaction is simply extended, this should increase the sensitivity of the 
assay. However, the substrates used are inherently unstable and therefore produce signal even 
in the absence of enzyme. This leads to a technical background signal that can mask the signal 
generated by the sandwich complex, making quantification difficult at low concentrations. In 
the end, the ability of the sandwich complex to correctly represent the concentration of the 
biomarker in a sample strongly depends on the quality of the antibodies used. If the antibodies 
cross-react with other substances, a signal can be measured even in the absence of the target 
analyte. Since the blood is much denser in protein content than is CSF, the risk for this is 
higher in the former, where even minor (e.g., 0.1%) cross-reactivity against proteins present at 
one million times higher concentrations will have a large impact on the measured 
concentration.  
 
For the problem with background, new ultrasensitive technologies provide a number of 
solutions. Most of these technologies rely on antibody-based detection of the target molecule, 
but in Single molecule array (Simoa), the detection reaction is compartmentalized into a small 
volume (50 femtolitres), so that the reporter molecule accumulates at a very high 
concentration,32 in Single molecule counting (Singulex), the labelled detection antibodies, 
specifically captured by the target molecule/capture antibody complex, are released and 
counted one by one in a small detection cell, which allows for a single molecule read-out,33 
and in proximity extension assay (PEA), partly overlapping complementary DNA strands are 
attached to the different antibodies allowing the strands to form a polymerase chain reaction-
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amplifiable template if immobilised close to each other on the same molecule.34 These 
variations in signal generation/detection may result in assays that can be 10- to a 1000-fold as 
sensitive as the corresponding regular ELISA using the same antibody pair.  
 
When using antibody-based assays on plasma or serum samples, it is essential to evaluate the 
assay for potential interference of human anti-mouse antibodies (HAMAs). These are 
heterophilic antibodies that can bind mouse (or other species) antibodies and bridge the 
capture and detection antibodies, thereby replacing the analyte and giving a falsely high 
signal.26 The prevalence in humans of such antibodies may be around 5%.35 There are several 
commercially available blockers against HAMAs; most are simply based on the addition of an 
excess of polyclonal mouse IgG that would sequester any interfering antibodies.  
 
Mass spectrometry (MS)-based assays are increasingly important in clinical laboratory 
medicine, mostly to measure small molecules, such as drugs, amino acids, hormones and 
vitamins in an antibody-independent manner.36 Mass spectrometers are also used in 
explorative proteomics studies to identify new biomarker candidates. However, explorative 
proteomics has so far failed to generate validated TBI biomarkers and, in general, MS-based 
standardised quantification of peptides and proteins for routine diagnostic use remains rare.37 
There are so far no established MS-based assays for TBI biomarkers, but this may well 
change during the coming years thanks to rapid technical development.  
 
 
Fluid biomarkers for acute TBI 
A schematic representation of established and candidate fluid biomarkers for neuronal, 
axonal, oligodendrocytic, astroglial and blood-brain barrier injury, as well as 
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neuroinflammation, in TBI is given in Figure 1. Since TBI is a condition with a distinct onset 
and since there are different phases of pathophysiological responses post-TBI,38 the timing of 
the biomarker sampling is crucial. If the intended use of the biomarker candidate is to 
quantify the initial damage, such a biomarker should probably be examined as early as 
possible, taking biomarker kinetics into account, whilst a biomarker for a delayed response, 
e.g., neuroinflammation or Wallerian degeneration, may be negative at early time points and 
reach its maximum concentration days, or even weeks to months, following the trauma 
(Figure 2). Below, we give a detailed account of the biomarker candidates for acute TBI that 
have been examined so far.   
 
Neuronal injury 
Neuron-specific enolase (NSE) is a glycolytic enzyme that converts 2-phosphoglycerate to 
phosphoenolpyruvate.39 The protein is enriched in neuronal cell bodies,40 but is also found in 
neuroendocrine cells, oligodendrocytes, blood platelets, and at particularly high 
concentrations in erythrocytes.39,41 This is the major limitation of the maker; also invisible 
haemolysis will contaminate the sample.42  
 
NSE concentrations are higher in ventricular CSF from non-survivors compared with 
survivors hours to days following severe TBI and correlate with other TBI severity scores in 
both adults and children.43-47 To what extent these findings depend on release of NSE from 
injured neurons or lysed erythrocytes is currently unknown; studies in which NSE 
concentration is related to free haemoglobin are needed.  
 
Numerous studies have examined NSE in serum as a potential biomarker for mild TBI. Initial 
results were promising showing increased serum NSE concentrations in samples taken from 
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patients with mild TBI within a few hours post-injury,48-50 but when scrutinizing the data, the 
overlap with non-concussed controls makes the diagnostic utility uncertain. One study 
examined the diagnostic performance of serum NSE concentration at 3 hours post-injury to 
identify intracranial lesions in mild TBI and found a sensitivity and specificity of 56% and 
77%, respectively.51 A recent study on sports-related concussion also produced disappointing 
results with no increase in serum NSE concentration over hours to days following concussion 
compared with preseason concentrations.52 Altogether, serum NSE does not appear to be a 
sensitive enough blood biomarker for mild TBI.  
 
Another protein enriched in the cytoplasm of neurons and a candidate biomarker for TBI is 
ubiquitin C-terminal hydrolase-L1 (UCHL1). However, UCHL1 is also expressed in neurons 
of the peripheral nervous system,53 as well as in cells of the neuroendocrine system,54 
endothelial and smooth muscle cells,55 and in some tumours.56 Nevertheless, increased serum 
and CSF concentrations of UCHL1 have been reported in patients with severe TBI with the 
highest concentrations seen within 24 hours post-injury in patients with poor outcome.57 Quite 
a number of papers have examined serum UCHL1 as a potential biomarker for mild TBI but 
the studies have been small and the results inconsistent.58 In one of the larger studies, UCHL1 
concentrations measured in serum samples collected within 4 hours post-injury from patients 
with mild (n=86) and moderate (n=10) TBI, as well as from trauma and non-trauma controls, 
were increased in both TBI groups compared with the control groups.59 Another study 
reported that serum UCHL1, taken within 24 hours post-injury, could distinguish mild TBI 
patients with intracranial lesions from those without intracranial lesions with an area under the 
curve of 0.713,60 a result that calls for additional replication studies.  
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Yet another protein with enhanced expression in neurons, as compared to other tissues, is 
brain-derived neurotrophic factor (BDNF). This protein is a member of the nerve growth 
factor family and activation of its intracellular receptors may produce neural regeneration, 
reconnection, and dendritic sprouting.61 One could imagine that neuronal injury in TBI would 
result in increased fluid concentrations of this potential biomarker but instead it appears like 
insufficient release of the protein may be related to poor outcome; in a recent study, day-of-
injury serum BDNF concentrations were lower in TBI patients compared with controls, 
particularly so in cases with severe TBI.62 However, another recent study performed in plasma 
did not support an association of BDNF concentration with outcome.63   
 
Axonal injury 
The best-established CSF biomarkers for axonal injury are tau and neurofilament light (NF-L) 
and heavy (NF-H).64 Tau is a microtubule-associated protein abundant in axons, but can also 
be detected in liver, kidney and testis.65 Further, a larger isoform of tau (called “big tau”), 
containing the epitopes used to measure tau with the currently available immunoassays, is 
expressed in peripheral nerves.66 Phosphorylation of tau is a physiological phenomenon but 
hyper-phosphorylation and aggregation into neurofibrillary tangles is characteristic of 
Alzheimer’s disease and CTE.65 In CSF, it is possible to measure both total tau (T-tau; with 
assays that do not discriminate between unphosphorylated and phosphorylated forms of tau, 
or between tau molecules translated from differently spliced mRNAs) and phosphorylated tau 
(P-tau; with sandwich immunoassays in which at least one of the antibodies is specific to a 
phosphorylated epitope of tau).  
 
NF-L and NF-H are also structural axonal proteins but, in contrast to tau that is predominantly 
expressed in thin unmyelinated axons of the cortex,67 the expression of neurofilaments is high 
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in large-calibre myelinated axons that extend subcortically.68 Expression is also detected in 
peripheral nerves.68  
 
T-tau concentrations in ventricular CSF correlate with lesion size and outcome in severe TBI, 
so that high levels indicate worse injury.69-71 In contrast, CSF P-tau concentration, as 
measured by currently available P-tau assays, is unchanged in TBI and other forms of acute 
brain injury.72,73 Studies on mild TBI show increased CSF concentrations of both T-tau and 
NF-L, but the magnitude of the increase of CSF NF-L is greater than for T-tau, suggesting 
that blows to the head impact long, large-calibre axons that extend subcortically more than 
short, non-myelinated axons in the cortex.73,74 Similar results as for NF-L have been observed 
for CSF NF-H.75  
 
Serum tau concentrations have been examined in both paediatric and adult patients with mild 
TBI and related to findings on CT scans of the brain. Concussed patients showed increased 
serum tau concentrations as compared to non-concussed controls,76,77 but there was no 
difference between patients with a positive or negative CT scan.76,78 However, in these 
studies, a regular tau ELISA, not optimised for the low concentrations of tau in the blood and 
not containing blockers against heterophilic antibodies in the sample diluent, was used, 
making the data uncertain. In moderate and severe TBI, requiring treatment at a 
neurointensive care unit, serum NF-L concentration measured by regular ELISA was 
increased, but no correlation with DAI or intracranial damage assessed by CT was seen.79 
 
Standard ELISAs for T-tau and NF-L were recently transferred onto the Single molecule array 
(Simoa) platform, which allows for the ultrasensitive measurement of these two proteins in 
the blood.80,81 Plasma T-tau concentration correlates poorly with CSF concentration,82 but in 
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acute hypoxic brain injury, a biphasic release of tau into the bloodstream was observed with a 
first peak occurring during the first few hours post-injury and a second broad peak occurring 
after a few more days; these increases were predictive of outcome.80 In a study on concussed 
professional ice hockey players, plasma T-tau concentration at 1 hour post-injury was 
increased compared with preseason concentrations and predicted return-to-play time with 
high accuracy.52 In another study of 34 patients with varying degree of TBI, plasma tau 
concentration in samples collected within 24 hours post-injury showed high accuracy to 
differentiate complicated mild TBI from controls (area under the curve 0.901).83 Recently, 
Olivera et al. reported increased mean plasma tau concentration in military personnel with a 
history of self-reported TBI compared with controls without such a history.84 Additionally, 
post-concussive symptoms correlated with plasma tau concentration in the TBI group, 
suggesting that the increase, although variable, might be of pathophysiological relevance.84  
 
Tau can be proteolytically cleaved by activated caspases and calpains in axonal injury, which 
generates fragments that can be measured in blood. Serum tau fragment concentrations in 
concussed ice hockey players were variable but peaked at 12 hours post-injury with the 
highest concentrations seen in those for whom it took longer than 10 days to become 
asymptomatic.85 Serum tau fragments did not correlate with post-concussive symptoms at 
three months following mild TBI, suggesting that it is not a late marker.86,87  
 
Serum NF-L concentration measured by Simoa correlated strongly with CSF NF-L,81,88 and 
increased over time in American football athletes over the course of a season,89 which may 
reflect head impacts, although it should be noted that changes were minor and that no direct 
assessment in relation to concussion has been performed to date. Gatson et al. examined 
serum concentrations of NF-H in mild TBI days 1 and 3 post-injury 90. At both time points, 
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serum NF-H concentrations were increased compared with concentrations in control 
individuals. Serum NF-H concentration was higher in CT-positive compared with CT-
negative patients, and was inversely correlated with clinical severity scores,90 which is a 
promising result in need of replication.  
 
The contribution of extra-cerebral sources of tau and neurofilaments to the results above is 
currently unknown and has to be carefully examined in future studies. However, for tau, 
plasma concentrations did not increase upon participation in an ice hockey game without 
incident concussions.52 These results contrast, e.g., S-100B and suggest that the brain-
enhanced expression of tau is high enough to make blood data interpretable in concussion.52  
 
αII-Spectrin breakdown products (SBDPs) have been described as potential biomarkers for 
brain injury in rats and humans.91,92 αII-Spectrin is abundant in axons and presynaptic 
terminals. In TBI and other forms of acute neuronal injury, the protein is processed to 
breakdown products by calpain and caspase-3 that are activated in dying neurons. SBDPs 
have been measured in ventricular CSF from patients with severe TBI and the concentrations 
correlate with clinical measures of TBI severity and outcome.93-95 In plasma, SBDP 
concentration increased within 24 hours after severe TBI.96 In mild TBI, also in some CT-
negative cases, serum SBDP concentration was also increased.97 Similar results were recently 
obtained in sports-related concussion (increased serum concentrations of SBDP 1 hour up to 6 
days post-injury).98  
 
Oligodendrocytic injury 
Myelin basic protein (MBP) is a major component of the myelin sheath made by 
oligodendrocytes of the central nervous system (CNS) and Schwann cells of the peripheral 
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nervous system.99 MBP is found at increased concentrations in the CSF of patients with 
demyelinating diseases such as multiple sclerosis.100 Since myelinated axons are thought to be 
primary targets in DAI, MBP has been suggested as a potential biomarker for TBI. The 
literature so far on the topic is scarce but MBP concentrations in CSF collected from 
extraventricular drains in severe paediatric TBI were found to be manifold increased as 
compared to CSF MBP concentrations in lumbar CSF from children evaluated for suspected 
CNS infection (the normal difference between interstitial fluid MBP and lumbar CSF MBP 
concentrations is unknown, however).101 Further, serum MBP concentration may be increased 
in paediatric TBI with intracranial haemorrhage compared with mild TBI without 
haemorrhage.102 Finally, increased serum MBP concentration has been detected in adult TBI 
patients with secondary brain hypoxia.103 Data from one study suggests that serum MBP 
concentration may peak later than S-100B and NSE; between 48 h and 72 h post-injury.102 
MBP may therefore have the greatest potential in post-acute mild TBI.  
 
Astroglial injury 
S-100B, an astrocyte-enriched Ca2+-binding protein, has been examined extensively in 
relation to TBI in serum, but studies on CSF are rare. Amateur boxers have slightly elevated 
CSF levels after bout, but the changes are not as pronounced as those for the axonal markers 
T-tau and NF-L.73 Similar results have been reported for glial fibrillary acidic protein 
(GFAP),73,74 which is an intermediate filament that is almost exclusively expressed in 
astrocytes.40 However, CSF GFAP has also been evaluated in the context if severe TBI and 
ventricular levels may improve outcome prediction models in conjunction with clinical data.95 
Clinically relevant changes in serum concentrations of S-100B and GFAP have been reported 
to detect radiographically apparent intracranial injury.104-106 The data from one of these 
studies suggested a slightly higher diagnostic accuracy for GFAP compared with S-100B, 
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particularly in patients with extracranial fractures that may give increased serum levels of S-
100B due to release of the protein from bone.107 S-100B has been included as a biomarker that 
could reduce the number of unnecessary CT scans of the brain in new clinical guidelines for 
the management of head injury.104 Still, this remains a controversial field; in a large 
convenience sample of adult trauma patients, the area under the curve of S-100B for detecting 
intracranial lesions on CT using serum samples obtained within 4 hours post-injury was only 
0.78 (95% confidence interval 0.67-0.89).106 A recent study of 34 patients with varying degree 
of TBI showed excellent accuracy of plasma GFAP to differentiate complicated mild TBI 
from controls (area under the curve 0.936 for samples collected during the first day post-
TBI).83  
 
Blood-brain barrier function 
Evidence from experimental and human autopsy studies indicate that blood-brain barrier 
disruption is common in TBI and may occur almost instantaneously.108 Following a head 
injury, cerebrovascular endothelial cells often incur mechanical deformation, as well as shear 
stress injury,109 leading to increased tight junction permeability and leakage of molecules 
across the blood-brain barrier. Theoretically, this would lead to increased concentrations of 
CNS-enriched molecules in the blood and increased concentrations of blood-derived 
molecules in the CSF.  
 
The best established clinical fluid biomarker for blood-brain barrier integrity is the 
CSF/serum albumin ratio (albumin produced by the liver has to cross the blood-brain barrier 
to reach the CSF).21 Some researchers caution against describing this measure as a blood-
brain barrier test and state that it actually reflects the blood-CSF barrier at the choroid 
plexus.110 However, in for example stroke, leaving the choroid plexus intact but injuring 
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cerebrovascular endothelial cells, the CSF/serum albumin ratio may be increased,111 
suggesting that CSF/serum albumin ratio probably is a marker of both barriers.  
 
Increased CSF/serum albumin ratio has been reported in patients with severe TBI.112,113 In 
mild TBI, no such changes have been seen,74,114 suggesting that the blood-brain barrier 
remains rather intact or only opens up transiently in mild TBI, or that the CSF/serum albumin 
ratio is not a sensitive enough marker of blood-brain barrier injury in mild TBI.  
 
It has been hypothesized that protein members of tight junctions could serve as plasma 
biomarkers for blood-brain barrier injury in TBI.115 One such protein is occludin, a 65-kDa 
integral membrane protein that contributes to tight junction stabilization at barriers.115 
However, this protein is not specific to the brain, but also expressed at high levels in testis, 
kidney, liver and lung.116 This may explain why increased plasma concentration of occludin 
has been observed, not only in concussed individuals, but also in patients with orthopaedic 
injury without concussion.117 
 
Neuroinflammation 
A large number of studies report an intrathecal acute phase inflammatory response following 
severe TBI, which is reflected in the CSF as increased concentrations of proinflammatory 
proteins such as IL-6, IL-8 and IL-10.112,113,118-128 Whether this reflects increased production 
of cytokines and interleukins within the CNS in response to the trauma, or leakage across a 
disrupted blood-brain barrier, or both, is unknown. The potential pathophysiological 
importance of the changes is supported by the association between a pro-inflammatory 
biomarker pattern and worse clinical outcome, not only in TBI,119,128 but also in other brain 
insults such as subarachnoid haemorrhage.129  
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In a pilot study including 16 paediatric patients with mild TBI and 20 paediatric patients who 
were scheduled for outpatient surgery but otherwise healthy, Berger et al. used multiplex bead 
technology to measure a large number of inflammatory proteins in serum.130 A combination 
of IL-6 and MMP-9 (increased serum concentrations of both in mild TBI) gave a sensitivity of 
81% and specificity of 94% for diagnosing the condition.130 This is a result in need of 
replication given the low number of included subjects. More recently, blood concentrations of 
inflammatory molecules, such as substance P, soluble CD40 ligand, and tissue inhibitor of 
matrix metalloproteinases, have been associated with outcome in TBI patients.131  
 
Hypermetabolism, mitochondrial dysfunction and oxidative stress 
Cerebral energy perturbation appears to play a major role in TBI, which might be detectable 
using markers of mitochondrial dysfunction, oxidative stress and metabolic changes. In the 
context of mild TBI, the literature is scarce but a well-recognised feature of severe TBI is 
elevation of brain extracellular lactate concentrations and the lactate/pyruvate (L/P) ratio, 
which is associated with unfavourable clinical outcome.132 A recent pilot study comparing 
profiles of amino acids and other small molecules in serum samples from moderate to severe 
TBI patients identified a pattern of changes in the concentrations of nine metabolites, which 
could distinguish patients who developed post-TBI cognitive impairment from those who did 
not.133 Another pilot study showed 2-to 7-fold increases in plasma concentration of the 
antioxidant enzyme peroxiredoxin 6 hours to days following mild to severe TBI compared to 
healthy, non-concussed control individuals. How these changes relate to post-TBI changes in 
the CNS is currently unknown. The findings are also in need of replication.  
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Explorative approaches 
To identify novel biomarkers for TBI, more or less unbiased discovery approaches, such as 
proteomics, lipidomics, antigen panels to detect auto-antibodies, exosome analyses, and 
microRNA arrays, have been used. So far, most studies have been conducted in TBI models 
and the literature on human TBI is limited. In two independent explorative proteomics studies 
on human samples, serum amyloid A (SAA) protein was identified as a potential blood 
biomarker for TBI.134,135 However, animal model data suggests that this is due to TBI-
associated up-regulation of SAA protein synthesis in the liver rather than the CNS injury per 
se.136 Other replicated findings from proteomics studies on TBI are currently lacking.  
 
Using antigen panels, some studies suggest that TBI with blood-brain barrier disruption may 
induce the production of auto-antibodies against CNS antigens that may even be of 
pathophysiological relevance and potentially influence long-term outcome.137 Pilot studies 
suggest that this may occur even upon repetitive subconcussive head blows in American 
football players.138 Another hot topic is whether TBI may induce release of 
exosomes/microvesicles/microparticles across the blood-brain barrier into the bloodstream. 
Pilot data indicate that this may occur in severe TBI,139 but to the best of our knowledge data 
on mild TBI is lacking. Finally, lipidomics-derived data on brain-enriched sphingolipids 
suggest that these increase in plasma from stroke patients,140 which would be interesting to 
explore further in TBI.  
 
Using microRNA arrays, elevated plasma levels of miR-16 and miR-92a in mild TBI were 
found, but the results are hard to interpret since severe TBI patients had lower levels and since 
the mild TBI levels were not different from those in orthopaedic injury patients.141 Starting 
with findings in a rat model of TBI, one study evaluated three significantly upregulated 
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microRNAs (miR-93, miR-191, and miR-499) in sera from TBI patients.142 Serum miR-93, 
miR-191, and miR-499 levels were significantly increased in the TBI patients compared with 
controls at all examined time points, and associated with TBI severity and outcome, calling 
for additional validation studies of these potential markers.    
 
 
Biomarkers in PCS 
As discussed above, symptoms of mild TBI usually resolve within days to weeks, but in 15% 
of concussion patients neurological symptoms persist for months or more.9,10 The relationship 
between repetitive mild TBI and development of PCS is poorly understood, specifically to 
what degree such long-lasting symptoms are due to neuronal damage, and to what degree 
psychogenic or psychosocial mechanisms play a role. It is also important to point out that 
PCS symptoms are not brain-specific; they are often found also in non-TBI subjects.143 
Standard blood-based biomarkers, such as S-100B, do not detect CNS injury in PCS but this 
may well be a sensitivity issue.144 In a recent pilot study of 16 patients with PCS and 15 
matched healthy control individuals, it was shown that a subset of the PCS patients (those 
with symptoms for more than 1 year, n=8) had increased CSF concentrations of NF-L, which 
indicates ongoing axonal injury, and decreased CSF concentrations of the 42 amino acid form 
of the A (A42), which may indicate A deposition in the brain parenchyma.145 These 
results warrant replication and also (if verified) long-term studies to assess whether this 
biomarker pattern may represent a prodrome of CTE.  
 
Chronic traumatic encephalopathy 
Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease associated with 
repetitive head trauma.16 There are no established neuroimaging or fluid markers of CTE,146 
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although the gross morphological changes seen in advanced CTE may be visualized using 
standard neuroimaging techniques.147  
 
In regards to in vivo markers of the molecular pathology in CTE, preliminary findings from 
positron emission tomography (PET) scanning using 2-(1-{6-[(2-[fluorine-
18]fluoroethyl)(methyl)amino]-2-naphthyl}-ethylidene)malononitrile (FDDNP), a ligand that 
binds to both neurofibrillary tangles and amyloid aggregates in the brain, of five retired 
players and five matched controls without a concussion history showed higher FDDNP 
signals in players compared with controls in all subcortical regions and the amygdala, which 
is a pattern distinct from that seen in Alzheimer’s disease.148 Similar results were recently 
reported in a larger case series.149 Selective amyloid PET imaging in TBI has yielded 
ambiguous data, possibly due to the diffuse nature of trauma-related amyloid deposits that are 
less prone to bind amyloid ligands than the neuritic plaques seen in Alzheimer’s disease.150 
No data on fluid markers of tau and Aβ pathology in CTE have been presented so far, 
although currently available CSF biomarkers for these two pathologies in Alzheimer’s 
disease, along with CSF NF-L, may be regarded as promising candidates. Clinical biomarker 
studies with longitudinal follow-up of patients with chronic or progressive symptoms after 
TBI are warranted to learn more about the pathogenesis, risk factors and clinical course of 
CTE.  
 
Concluding remarks 
When reviewing the biomarker literature on mild TBI, PCS and CTE, it is clear that the field 
remains young; a lot of work remains to be done to optimize sample collection (including 
sampling time points) and storage, to identify and mitigate pre-analytical and analytical 
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confounders and to optimize the employed assays to maximise their analytical sensitivity and 
specificity. Intense such work is ongoing in different research consortia.  
 
Another issue with biomarker research in mild TBI is that there is currently no established 
reference (or “gold”) standard validated against neuropathology to make the diagnosis. 
Further, the imaging methods are presently not sensitive enough to reliably detect mild TBI. 
We therefore have to rely on clinical criteria for mild TBI/concussion as the reference 
standard for making the diagnosis, which gives us rather heterogeneous groups to examine. 
This is an obvious limitation, but within such clinically diagnosed mild TBI groups, there may 
be individuals with more or less clear biomarker alterations. Longitudinal studies may then 
clarify whether mild TBI patients with more or less abnormal biomarker concentrations are 
more or less likely to develop PCS or related disorders. Predictive biomarker cut-points then 
have to be independently validated. Similarly, sample collections from patients with PCS, 
where there eventually may be autopsy data indicating CTE in some cases, will be useful to 
find biomarkers that predict CTE. All this will be iterative work, requiring extensive 
collaboration and sharing of materials, methods and samples.  
 
In regards to blood-based biomarkers for TBI, promising data exist on the detection of acute 
and potentially also delayed effects of TBI, but more replication and validation work needs to 
be done and more biomarker candidates are warranted. It should be noted that brain pathology 
in mild TBI may be rather subtle, which puts extra demand on the analytical performance of 
the employed assays; targeted analyses of key molecules using ultrasensitive technologies will 
likely be important in this context.  
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Several important issues in regards to the potential clinical usefulness of biomarkers for mild 
TBI could not be addressed in this review due to lack of data. For example, we have not been 
able to discuss what the optimal analytical platforms are (it is simply too early to make such 
claims), the potential of point-of-care testing, turnaround times in the emergency care unit and 
similar clinically highly relevant matters. The current state of this research field is that 
promising biomarker candidates exist but that the findings from individual studies, indicating 
potential clinical utility, now await independent replication. Once this requirement has been 
fulfilled and the clinical context of use for a certain biomarker has been established, the 
biomarker should be nominated for further standardisation work, including the development 
of certified reference materials and methods, to allow for proper assay standardisation, quality 
control and cut-point determination, and to optimise the technical aspects of the analytical 
methods to allow for rapid and cost-effective testing.  
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Box 1: Mild traumatic brain injury and related conditions 
Mild traumatic brain injury (concussion) Rapid-onset neuronal dysfunction caused by 
an external mechanical force to the brain 
without detectable gross pathology, such as 
haemorrhage 
Post-concussive syndrome A complex disorder in which various 
symptoms, such as headache and dizziness, 
last for weeks to months after concussion 
Chronic traumatic encephalopathy A progressive tauopathy mainly found in 
people with a history of repetitive head 
injuries 
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Figure 1: Candidate fluid biomarkers for pathophysiological processes related to traumatic 
brain injury (TBI). Tau and neurofilament light (NF-L) and heavy (NF-H), as well as spectrin 
breakdown products (SBDPs), are biomarkers for axonal injury. Neuron-specific enolase 
(NSE) and ubiquitin C-terminal hydrolase-L1 (UCHL1) are proteins enriched in the neuronal 
soma and putative biomarkers for neuronal injury. Activated astrocytes and microglia in TBI 
secrete S-100B and glial fibrillary acidic protein (GFAP), as well as interleukins, cytokines 
and matrix metalloproteinases. CSF/serum albumin ratio is an established biomarker for 
blood-brain and/or blood-CSF barrier integrity. Plasma occludin is a candidate biomarker in 
the blood for the same function.  
 
Figure 2: Hypothetical model of temporal brain changes in traumatic brain injury (TBI) not 
complicated by secondary insults. Blood-brain barrier disruption and axonal disconnection are 
thought to occur more or less instantaneously, probably together with fast astrocytic and 
microglial activation and induction of a hypermetabolic state that may induce long-term 
oxidative stress and mitochondrial dysfunction. Microglial activation may also linger and take 
part in a more delayed response with proper neuroinflammation. Wallerian degeneration may 
go on for months and even years following the injury and is signified by breakdown of axonal 
debris distal to the injury. The optimal time point for biomarker sampling will depend on what 
aspect of the TBI process the biomarker candidate is thought to reflect; this has to be carefully 
evaluated for each biomarker candidate in animal models and in human studies with repeated 
sampling over time.  
 
 
 
 
